Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tumor
100%
Overall Survival
87%
Chemotherapy
70%
Non-small Cell Lung Cancer (NSCLC)
67%
Phase II Study
67%
Breast Cancer
61%
Progression-free Survival
59%
Phase II Trial
57%
Confidence Interval
57%
Relapsed or Refractory
43%
Clinical Trials
40%
Rituximab
37%
Lung Cancer
34%
Metastatic Breast Cancer
33%
Targeted Therapy
31%
Hazard Ratio
30%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
29%
Mantle Cell Lymphoma
28%
Doxorubicin
27%
Radiation Therapy
26%
Follicular Lymphoma
26%
In Cancer
26%
Adverse Events
25%
Programmed Death-ligand 1 (PD-L1)
25%
Diffuse Large B-cell Lymphoma (DLBCL)
24%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
24%
Brentuximab Vedotin
24%
Cisplatin
23%
NCCN Guidelines
23%
Gemcitabine
23%
Circulating Tumor DNA (ctDNA)
23%
Colorectal Cancer
23%
Triple-negative Breast Cancer
22%
Complete Response
22%
Docetaxel
22%
Partial Response
22%
Clinical Outcomes
22%
Pancreatic Cancer
21%
Pembrolizumab
21%
Immune Checkpoint Inhibitors
21%
Oncology
21%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
20%
Overall Response Rate
20%
Solid Tumors
19%
Hodgkin Lymphoma
19%
Median Overall Survival
19%
Median Progression-free Survival
19%
Melanoma
19%
Carboplatin
19%
T Cells
19%
Objective Response Rate
19%
Lymphoma
19%
Monotherapy
18%
Phase I Study
18%
Non-Hodgkin Lymphoma
18%
Pancreatic Ductal Adenocarcinoma
18%
Older Adults
18%
Paclitaxel
18%
Bevacizumab
17%
Disease Progression
17%
High Risk
17%
Glioblastoma
17%
Randomized Phase II Trial
17%
Placebo
16%
Previously Treated
16%
Stable Disease
16%
Cyclophosphamide
16%
Dose Escalation
16%
Small Cell Lung Cancer
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Response Rate
16%
Antitumor Activity
16%
Tumor Cells
16%
Sarcoma
15%
Metastasis
15%
Systemic Therapy
15%
Peripheral T-cell Lymphoma
15%
Maximum Tolerated Dose
14%
Treatment Options
14%
Neutropenia
14%
Head-and-neck Cancer
14%
Soft Tissue Sarcoma
14%
Tumor Microenvironment
14%
Cetuximab
14%
Neoadjuvant
14%
Malignancy
13%
Chronic Lymphocytic Leukemia
13%
Prednisone
13%
Newly Diagnosed
13%
Older Patients
13%
United States
13%
Cancer Treatment
13%
Multiple Myeloma
13%
Radiotherapy
13%
Whole Genome
13%
Resection
13%
Cancer Types
13%
Treatment-related Adverse Events
13%
Colorectal Liver Metastases
13%
Standard of Care
12%
Medicine and Dentistry
Diseases
96%
Malignant Neoplasm
93%
Neoplasm
92%
Breast Cancer
91%
Overall Survival
89%
Non Small Cell Lung Cancer
72%
Tumor
61%
Progression Free Survival
58%
Clinical Trial
51%
Cancer
44%
Oncology
41%
Immunotherapy
40%
Radiation Therapy
38%
Metastatic Carcinoma
36%
Lung Cancer
32%
Rituximab
32%
Arm
30%
Targeted Therapy
30%
Recurrent Disease
29%
Adverse Event
29%
Biological Marker
27%
Melanoma
25%
Hodgkin's Lymphoma
25%
Mantle Cell Lymphoma
24%
Hazard Ratio
24%
Metastatic Breast Cancer
23%
T Cell
23%
Non-Hodgkin Lymphoma
23%
Diffuse Large B-Cell Lymphoma
22%
Connective Tissue Cancer
20%
Cisplatin
19%
Pembrolizumab
19%
Doxorubicin
18%
Pancreas Cancer
18%
Phase II Trials
18%
Triple Negative Breast Cancer
17%
Circulating Tumor DNA
17%
Paclitaxel
17%
Prostate Cancer
17%
Follicular Lymphoma
17%
Solid Malignant Neoplasm
17%
Small Cell Lung Cancer
17%
Pancreas Adenocarcinoma
16%
Immune Checkpoint Inhibitor
16%
Systemic Therapy
16%
Colorectal Carcinoma
16%
Cancer Cell
16%
Head and Neck Squamous Cell Carcinoma
15%
Brentuximab Vedotin
15%
Soft Tissue Sarcoma
15%
Gemcitabine
15%
Cancer Therapy
14%
Positron Emission Tomography
14%
Tumor Progression
14%
Peripheral T-Cell Lymphoma
14%
Placebo
14%
Chemoradiotherapy
14%
Glioblastoma
14%
Quality of Life
14%
Hormone Therapy
13%
Tumor Cell
13%
Epidermal Growth Factor Receptor
13%
Carcinogenesis
13%
Cyclophosphamide
13%
Treatment Option
12%
Multiple Myeloma
12%
Carboplatin
11%
B Cell
11%
B-Cell Chronic Lymphocytic Leukemia
11%
Squamous Cell Carcinoma
11%
Human Immunodeficiency Virus
11%
Disease Free Survival
11%
Head and Neck Cancer
11%
Neoadjuvant Chemotherapy
11%
Nivolumab
10%
Classical Hodgkin Lymphoma
10%
Systematic Review
10%
Colorectal Liver Metastasis
10%
Monotherapy
10%
Malignant Peripheral Nerve Sheath Tumor
10%
Primary Tumor
10%
Disease Exacerbation
9%
Survival Rate
9%
Neurofibromatosis Type I
9%
Programmed Death-Ligand 1
9%
Health Care Cost
9%
Bevacizumab
9%
Rectum Cancer
9%
Wart Virus
9%
Adjuvant Therapy
9%
Lung
9%
Adjuvant Chemotherapy
9%
B-Cell Lymphoma
9%
Estrogen Receptor
9%
Prognostic Factor
9%
Cetuximab
9%
Stem Cell Transplant
9%
Tumor Microenvironment
9%
Oral
9%
Hematopoietic Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
91%
Neoplasm
86%
Diseases
85%
Malignant Neoplasm
84%
Overall Survival
82%
Non Small Cell Lung Cancer
78%
Progression Free Survival
68%
Breast Cancer
54%
Clinical Trial
44%
Adverse Event
43%
Rituximab
41%
Paclitaxel
32%
Solid Malignant Neoplasm
30%
Doxorubicin
28%
Metastatic Breast Cancer
28%
Phase II Trials
27%
Lung Cancer
26%
Nonhodgkin Lymphoma
26%
Biological Marker
24%
Prostate Cancer
24%
Immunotherapy
23%
Follicular Lymphoma
21%
Docetaxel
21%
Cisplatin
21%
Small Cell Lung Cancer
20%
Diffuse Large B Cell Lymphoma
20%
Gemcitabine
20%
Carboplatin
19%
Mantle Cell Lymphoma
19%
Cyclophosphamide
19%
Placebo
18%
Recurrent Disease
18%
Epidermal Growth Factor Receptor
18%
Monotherapy
17%
Melanoma
16%
Pharmacokinetics
16%
Hodgkin Disease
15%
Chemoradiation Therapy
15%
Colorectal Carcinoma
15%
Pembrolizumab
15%
Bevacizumab
15%
Glioblastoma
15%
Pancreas Cancer
14%
Head and Neck Squamous Cell Carcinoma
14%
Neutropenia
14%
Pancreas Adenocarcinoma
14%
Cetuximab
13%
Antitumor Activity
13%
Disease Exacerbation
13%
Remission
13%
Maximum Tolerated Dose
13%
Carcinogenesis
13%
Brentuximab Vedotin
12%
Etoposide
12%
Tumor Growth
12%
Bendamustine
12%
Vincristine
12%
Immune Checkpoint Inhibitor
12%
Triple Negative Breast Cancer
12%
Tolerability
12%
Prednisone
12%
Soft Tissue Sarcoma
11%
Survival Rate
11%
Phase III Trials
11%
Circulating Tumor DNA
11%
Diarrhea
10%
Chronic Lymphatic Leukemia
10%
Leukemia
9%
Nivolumab
9%
Endocrine Therapy
9%
Bortezomib
9%
Lenalidomide
9%
Castration Resistant Prostate Cancer
9%
Palbociclib
9%
Connective Tissue Cancer
9%
Estrogen Receptor
9%
Receptor
9%
Cyclin Dependent Kinase 4
9%
Pemetrexed
9%
Combination Therapy
9%
Disease Free Survival
8%
Squamous Cell Carcinoma
8%
Thrombocytopenia
8%
Hormone Receptor
8%
Anemia
8%
Irinotecan
8%
Transitional Cell Carcinoma
8%
Renal Cell Carcinoma
8%
Peripheral T Cell Lymphoma
8%
Temozolomide
8%
Erlotinib
7%
Metastatic Colorectal Cancer
7%
Colon Carcinoma
7%
Gamma Urogastrone
7%
Nausea
7%
Phase I Trials
7%
Liver Cell Carcinoma
7%
Phosphatidylinositol 3 Kinase
7%
Methotrexate
7%
Everolimus
7%